The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) commissioned Charles River Associates to review the evidence on the value of innovation for diabetes in middle-income countries (MICs) and test the extent to which the experience of these countries is aligned with the experience of high-income countries (HICs). The report provides an overview of the therapeutic and wider societal value of type-2 diabetes (T2D) medicines in China. China is the MIC with the largest number of people with T2D and has recognized T2D to be an escalating challenge.
Digital Health Technologies: The Evolving Landscape Of Reimbursement & 4 Strategies To Consider
The use of digital health technologies (DHTs), ranging from devices and apps to cloud-based services and artificial intelligence platforms, has accelerated...